⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Official Title: A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS

Study ID: NCT00002742

Study Description

Brief Summary: RATIONALE: Antifungal therapy with liposomal nystatin may reduce fever and neutropenia in patients undergoing treatment for hematologic cancer. It is not yet known whether liposomal nystatin is more effective than standard amphotericin B in treating patients with fever and neutropenia who are receiving chemotherapy for hematologic cancer or bone marrow transplantation for leukemia. PURPOSE: Randomized phase III trial to study the effectiveness of liposomal nystatin compared with standard amphotericin B to treat fever and neutropenia in patients receiving chemotherapy for hematologic cancer or bone marrow transplantation for leukemia.

Detailed Description: OBJECTIVES: I. Compare the efficacy of liposomal nystatin vs standard amphotericin B for the empiric treatment of persistent febrile neutropenic patients. II. Compare the incidence of drug-related toxicity or impairment and infusion-related toxicity in patients treated with liposomal nystatin vs standard amphotericin B. III. Determine the pharmacokinetics of liposomal nystatin. OUTLINE: Randomized, double-blind study. Arm I: Antifungal Therapy. Liposomal Nystatin. Arm II: Antifungal Therapy. Amphotericin B, NSC-527017. PROJECTED ACCRUAL: 350 evaluable patients will be studied in this multicenter trial.

Eligibility

Minimum Age: 2 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, United States

Holt-Krock Clinic, Fort Smith, Arkansas, United States

Arkansas Children's Hospital, Little Rock, Arkansas, United States

Office of Rosalda Rodriguez, M.D., Chula Vista, California, United States

Beckman Research Institute, City of Hope, Duarte, California, United States

Eisenhower Medical Center, Rancho Mirage, California, United States

University of Colorado Cancer Center, Denver, Colorado, United States

New Britain General Hospital, New Britain, Connecticut, United States

Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States

Sylvester Cancer Center, University of Miami, Miami, Florida, United States

Tampa Children's Hospital, Tampa, Florida, United States

Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

St. John's Pavilion - Springfield Clinic Research Department, Springfield, Illinois, United States

University of Kansas Medical Center, Kansas City, Kansas, United States

Lake Charles Medical and Surgical Clinic, Lake Charles, Louisiana, United States

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Boston University School of Medicine, Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Henry Ford Hospital, Detroit, Michigan, United States

United Hospital, Saint Paul, Minnesota, United States

Columbia Comprehensive Cancer Care Clinic, Columbia, Missouri, United States

University of Missouri-Columbia Hospital and Clinics, Columbia, Missouri, United States

Children's Mercy Hospital - Kansas City, Kansas City, Missouri, United States

Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States

Antibiotic Research Associates, Kansas City, Missouri, United States

University of Nebraska Medical Center, Omaha, Nebraska, United States

Hackensack University Medical Center, Hackensack, New Jersey, United States

Jersey Shore Cancer Center, Neptune, New Jersey, United States

Riverview Medical Center, Red Bank, New Jersey, United States

Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States

Brooklyn Hospital Center, Brooklyn, New York, United States

Roswell Park Cancer Institute, Buffalo, New York, United States

Long Island Jewish Medical Center, New Hyde Park, New York, United States

St. Vincent's Medical Center of Richmond, Staten Island, New York, United States

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Brookview Research, Inc., Winston-Salem, North Carolina, United States

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Summa Health System, Akron, Ohio, United States

Ireland Cancer Center, Cleveland, Ohio, United States

Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

Office of Ian Baird & Mark Herbert, Columbus, Ohio, United States

Infectious Disease Associates of N.W. Ohio, Toledo, Ohio, United States

Northeast Ohio Infectious Disease Associates, Inc., Youngstown, Ohio, United States

Medical Specialists, Inc., Zanesville, Ohio, United States

University of Oklahoma - Department of Pharmacy Practice, Oklahoma City, Oklahoma, United States

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

University of Tennessee Medical Center at Knoxville, Knoxville, Tennessee, United States

Baptist Clinical Research Services, Memphis, Tennessee, United States

Texas Cancer Center at Brackenridge Hospital, Austin, Texas, United States

University of Texas Southwestern Medical School, Dallas, Texas, United States

Infectious Disease Associates of Houston, Houston, Texas, United States

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Wilford Hall - 59th Medical Wing, Lackland Air Force Base, Texas, United States

South Texas Oncology and Hematology, San Antonio, Texas, United States

Scott and White Clinic, Temple, Texas, United States

Infections Limited, P.S., Tacoma, Washington, United States

Contact Details

Name: David S. Gordon, MD

Affiliation: Aronex Pharmaceuticals

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: